In brief: poor metabolizers of clopidogrel (plavix).
出版信息
Med Lett Drugs Ther. 2010 May 3;52(1337):33.
PMID:20431520
Abstract
摘要
相似文献
1
In brief: poor metabolizers of clopidogrel (plavix).
Med Lett Drugs Ther. 2010 May 3;52(1337):33.
2
Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Clin Pharmacol Ther. 2011 Feb;89(2):229-33. doi: 10.1038/clpt.2010.268. Epub 2010 Dec 22.
3
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Lancet. 2009 Apr 4;373(9670):1171-2; author reply 1172-3. doi: 10.1016/S0140-6736(09)60680-2.
4
Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
Gen Dent. 2010 Jan-Feb;58(1):7-9.
5
Clopidogrel pathway.
Pharmacogenet Genomics. 2010 Jul;20(7):463-5. doi: 10.1097/FPC.0b013e3283385420.
6
Cytochrome P-450 polymorphisms and response to clopidogrel.
N Engl J Med. 2009 May 21;360(21):2249-50; author reply 2251. doi: 10.1056/NEJMc090391.
7
Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
Am J Health Syst Pharm. 2011 Mar 15;68(6):529-32. doi: 10.2146/ajhp100422.
8
Clopidogrel poor metabolizers may need alternative to standard regimen.
Am J Health Syst Pharm. 2010 May 15;67(10):779-80. doi: 10.2146/news100036.
9
Clopidogrel, genetics, and drug responsiveness.
N Engl J Med. 2009 Jan 22;360(4):411-3. doi: 10.1056/NEJMe0810513.
10
PPI interactions with clopidogrel revisited.
Med Lett Drugs Ther. 2009 Feb 23;51(1306):13-4.
Zotero 插件